Editorial
|
|
|
|
|
Explanatory versus pragmatic trials
|
|
|
|
Marketing Authorisations
|
|
|
|
|
No better than levonorgestrel
|
|
|
|
|
|
|
|
|
|
|
|
Useful for selected adult travellers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No evidence of benefits on hard endpoints
|
|
|
|
|
|
|
|
|
|
Better emollients are available
|
|
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Digoxin assay and clinical monitoring
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The first year of therapy is crucial
|
|
|
|
|
|
|
|
|
|
|
|
Updates from regulators and WHO
|
|
|
|
|
|
|
|
|
|
|
|
Confirmation of adverse effect profile
|
|
|
|
|
|
|
|
|
|
Unfavourable risk-benefit balance
|
|
|
|
|
|
Reviews
|
|
|
|
|
The drugs that Prescrire rated “nothing new” or "unacceptable” in 2009, listed by category of conditions treated
|
|
|
|
|
|
|
|
|
|
Clinical pointers to a difficult diagnosis
|
|
|
|
|
|
|
|
|
|
Efficacy not yet demonstrated
|
|
|
|
Outlook
|
|
|
|
|
Many novelties exposing patients to unjustified harms
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nearly 20% of new drugs authorised in France rated "not acceptable"
|
|
|
|
|
|
|
|